FZD4 and age-related macular degeneration: Our observation that F4L5.13 resolves CE further validates the norrin/FZD4 signaling pathway as a compelling target for drug development in ME, for example in diabetic retinopathy, age-related macular degeneration, or retinal occlusive disease.